1405-10-3 Neomycin sulfate High Purity CAS NO.1405-10-3

Neomycin is an aminoglycoside antibiotic produced by S. fradiae that inhibits protein translation by binding to the small subunit of prokaryotic ribosomes. It blocks voltage-sensitive Ca²⁺ channels and is a potent inhibitor of skeletal muscle sarcoplasmic reticulum Ca²⁺ release. Neomycin has been shown to inhibit inositol phospholipid turnover, phospholipase C, and phosphatidylcholine-phospholipase D activity (IC₅₀ = 65 µM). It is highly effective against Gram-positive and Gram-negative bacteria and is commonly used for the prevention of bacterial contamination of cell cultures.

Neomycin sulfate is an aminoglycoside antibiotic and calcium channel protein inhibitor. Neomycin sulfate also binds to prokaryotic ribosomes inhibiting translation and is effective against gram-positive and gram-negative bacteria. Neomycin sulfate inhibits PLC (Phospholipase C) via binding to inositol phospholipids. It also inhibits phosphatidylcholine-PLD activity and induces Ca²⁺ mobilization and PLA2 activation in human platelets. Neomycin sulfate inhibits DNase I induced DNA degradation.

Neomycin, one of the many oligosaccharide containing antibiotics, is an aminoglycoside antibiotic found in Streptomyces fradiae (Collins, 2006) with wide spectrum, active against Gram-negative Gram-positive bacteria. Neomycin is commony used as a selection marker in cloning, and is therefore used in growth media to select colonies with the neomycin resistance cassette integrated into their genome. Neomycin is a mixture of neomycin B (Framycetin) and its epimer Neomycin C, the latter component accounting for some 5–15% of the mixture.